Investment Rating - The investment rating for the company is "Accumulate" with a target price of 177.30 CNY [6][12]. Core Insights - The company, WuXi AppTec, is a leading global CRDMO player, with its 2025 performance exceeding guidance, showing a significant profit margin increase. The Tides business is strong, with a backlog of orders increasing by 28% by the end of 2025, and a projected revenue growth of 18-22% for 2026 [2][12]. Financial Summary - Total revenue for 2025 was 45,456 million CNY, a year-on-year increase of 15.8%, surpassing the revised guidance. The net profit attributable to shareholders reached 19,151 million CNY, up 102.6% year-on-year. The adjusted Non-IFRS net profit was 14,960 million CNY, reflecting a 41.3% increase [4][12]. - The company forecasts revenues of 52,405 million CNY, 60,176 million CNY, and 66,900 million CNY for 2026, 2027, and 2028, respectively, with growth rates of 15.3%, 14.8%, and 11.2%. The net profit attributable to shareholders is expected to be 17,638 million CNY, 20,442 million CNY, and 22,375 million CNY for the same years, with growth rates of -7.9%, 15.9%, and 9.5% [12][13]. - The adjusted Non-IFRS gross margin improved to 48.2%, a year-on-year increase of 6.6 percentage points, driven by higher capacity utilization and an increase in high-margin business [12]. Business Performance - The chemical business generated revenue of 36,470 million CNY, a 25.5% year-on-year increase. The small molecule CDMO pipeline expanded, with revenue from small molecule D&M business reaching 19,920 million CNY, up 11.4% year-on-year [12]. - The Tides business saw revenue of 11,370 million CNY, a remarkable growth of 96% year-on-year, with a backlog of orders increasing by 20.2%. The number of clients for TIDES D&M services rose by 25%, and the number of service molecules increased by 45% [12].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 177.30 CNY [6][12]. Core Insights - The company, WuXi AppTec, is a leading global CRDMO player, with its 2025 annual performance exceeding guidance, showing a significant profit margin increase. The Tides business is strong, with a backlog of orders increasing by 28% as of the end of 2025, and a projected revenue growth of 18-22% for 2026 [2][12]. Financial Summary - Total revenue for 2025 was 45,456 million CNY, a year-on-year increase of 15.8%, surpassing the revised revenue guidance. The net profit attributable to shareholders was 19,151 million CNY, up 102.6% year-on-year. The adjusted Non-IFRS net profit was 14,960 million CNY, reflecting a 41.3% increase [4][12]. - The company expects revenues for 2026 to be between 52,405 million CNY and 53,000 million CNY, with a growth rate of 15.3% [12]. - The gross margin for adjusted Non-IFRS increased to 48.2%, up 6.6 percentage points year-on-year, driven by improved capacity utilization and a higher proportion of high-margin businesses [12]. Business Segments - The chemical business generated revenue of 36,470 million CNY in 2025, a 25.5% increase. The small molecule CDMO pipeline continues to expand, with 199,200 million CNY in revenue, an 11.4% increase, and a total of 3,452 molecules in the pipeline [12]. - The Tides business saw revenue of 11,370 million CNY in 2025, a remarkable 96% increase, with a backlog of orders growing by 20.2% [12]. Future Projections - For 2026-2028, the company forecasts revenues of 52,405 million CNY, 60,176 million CNY, and 66,900 million CNY, with growth rates of 15.3%, 14.8%, and 11.2% respectively. The net profit attributable to shareholders is projected to be 17,638 million CNY, 20,442 million CNY, and 22,375 million CNY for the same years, with growth rates of -7.9%, 15.9%, and 9.5% respectively [12][13].

Financial Data and Key Metrics Changes - Revenue reached RMB 21.8 billion, a 16.7% increase from 2024, with a sequential growth of about 18% in the second half compared to the first half [25][26] - Adjusted net profit increased by 22% year-over-year to RMB 6.6 billion, with a margin expansion of 130 basis points to 30.2% [32][34] - Adjusted EBITDA rose by 22.8% to RMB 9.8 billion, with an adjusted EBITDA margin of 45.1%, one of the highest in the global CDMO industry [32][34] Business Line Data and Key Metrics Changes - Research and discovery services saw a doubling of upfront payments to $115 million, with potential milestone income streams exceeding $4 billion [27] - Development revenue grew by approximately 32% year-over-year, driven by 209 new projects, with 186 in the pre-IND space [28] - Manufacturing revenue from late-phase and commercial projects grew over 26% year-over-year, now representing over 43% of the total portfolio [29] Market Data and Key Metrics Changes - The U.S. accounted for 58% of revenue, growing over 18%, while Europe contributed 23% with nearly 17% growth [16] - Japan and Korea experienced significant growth of almost 70%, now representing 6.5% of total revenue [16][17] - China saw a slight decline in revenue, but adjusting for out-licensing deals shows nearly flat year-over-year growth [17][18] Company Strategy and Development Direction - The company emphasizes a unique CRDMO business model, focusing on bi-specifics, ADCs, and traditional mAbs to drive sustainable high growth [3][4] - The strategy includes expanding capabilities in complex modalities, which are expected to enhance market share due to their challenging nature [20][21] - Continuous investment in technology and capacity expansion in key markets like the U.S. and Singapore is planned to support future growth [59][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledges geopolitical uncertainties but remains optimistic about sustained growth driven by a strong project funnel and client trust [8][14] - The company expects to continue delivering high growth, with a focus on maintaining a sticky project funnel despite external challenges [14][19] - Future revenue growth is anticipated from the successful execution of projects and the introduction of new technologies [58][64] Other Important Information - The company reported a significant increase in gross profit, reaching over RMB 10 billion, with a 31% increase in gross profit margin [30][37] - The company has a strong balance sheet with RMB 15.7 billion in cash, supporting accelerated global growth [41][43] - The company is committed to continuous improvement through the WuXi Business System, achieving a 150 basis points improvement in margin [70] Q&A Session Summary Question: What are the key drivers of revenue growth? - Revenue growth was driven by R&D services, particularly in bispecifics and ADCs, with a strong pipeline of new deals expected to continue into 2026 [27][28] Question: How does the company plan to manage geopolitical risks? - The company acknowledges the geopolitical noise but emphasizes the stickiness of its project funnel and strong client relationships as mitigative factors [8][14] Question: What is the outlook for the manufacturing segment? - The manufacturing segment is expected to grow significantly, with a focus on late-phase projects and commercial manufacturing, which have shown strong revenue growth [29][30]

Financial Data and Key Metrics Changes - Revenue reached RMB 21.8 billion, a 16.7% increase from 2024, with a sequential growth of about 18% in the second half compared to the first half [25][26] - Adjusted net profit increased by 22% year-over-year to RMB 6.6 billion, with a margin expansion of 130 basis points to 30.2% [32][33] - Basic earnings per share grew from $0.82 to $1.22, a 49% increase [36] Business Line Data and Key Metrics Changes - Research and discovery services saw a doubling of upfront payments to $115 million, with potential milestone income streams exceeding $4 billion [26][27] - Development revenue grew by about 32% year-over-year, driven by 209 new projects, with 186 in the pre-IND space [28] - Manufacturing revenue from late-phase and commercial projects grew over 26% year-over-year, now representing over 43% of the total portfolio [29] Market Data and Key Metrics Changes - U.S. revenue accounted for 58% of total revenue, growing over 18%, while Europe contributed 23% with nearly 17% growth [16] - Japan and Korea experienced almost 70% growth, now making up 6.5% of total revenue [16] - China saw a slight decline in revenue, but adjusting for out-licensing deals shows a flat year-over-year growth [17] Company Strategy and Development Direction - The company emphasizes a unique CRDMO business model, focusing on bi-specifics, ADCs, and traditional mAbs to drive sustainable growth [3][4] - The strategy includes expanding capabilities in complex modalities, which are expected to enhance market share due to their challenging nature [20] - Continuous investment in technology and capacity expansion is planned, particularly in the U.S. and Singapore, to support future growth [59][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledges geopolitical uncertainties but remains optimistic about revenue growth driven by a strong project funnel and backlog [25][30] - The company expects to maintain momentum in R&D and development services, with a focus on innovative platforms and complex modalities [26][28] - Future revenue growth is anticipated from the successful execution of projects and the expansion of manufacturing capabilities [29][58] Other Important Information - The company reported a significant increase in gross profit, reaching over RMB 10 billion, a 31% increase year-over-year [30] - The adjusted gross profit margin reached 48.8%, with a 340 basis points improvement year-over-year [37] - The company has a strong balance sheet with RMB 15.7 billion in cash, supporting accelerated global growth [41] Q&A Session Summary Question: What is the outlook for revenue growth in the coming years? - Management indicated that the revenue growth is expected to continue, driven by a strong project pipeline and successful execution of existing projects [25][30] Question: How does the company plan to address geopolitical uncertainties? - The company is focusing on diversifying its revenue streams and maintaining strong relationships with clients to mitigate risks associated with geopolitical issues [25][30] Question: What are the key drivers for the growth in the U.S. and European markets? - The growth in these markets is attributed to the increasing demand for complex modalities and the successful execution of large-scale projects [16][29]

Investment Rating - The investment rating for the company is "Accumulate" [3][5] Core Insights - The company achieved strong growth in 2025, with total revenue reaching 45.456 billion yuan, a year-on-year increase of 15.84%. The revenue from continuing operations grew by 21.40% [3][4] - The net profit attributable to shareholders was 19.151 billion yuan, representing a significant year-on-year increase of 102.65%. The adjusted net profit under Non-IFRS was 14.96 billion yuan, up 41.3% year-on-year [3][4] - The company expects 2026 revenue to reach between 51.3 billion and 53 billion yuan, with a year-on-year growth of 18%-22% for continuing operations [3][4] Summary by Relevant Sections Financial Performance - In 2025, the company reported a total revenue of 45.456 billion yuan, with a 15.84% increase from the previous year. The revenue from WuXi Chemistry was 36.47 billion yuan, up 25.5%, benefiting from process optimization and capacity efficiency improvements [3][4] - The adjusted Non-IFRS gross margin for WuXi Chemistry improved by 5.9 percentage points to 52.3% [3] - The company’s overall continuing operations backlog reached 58 billion yuan, a year-on-year increase of 28.8%, indicating strong long-term visibility for performance [3] Business Segments - WuXi Chemistry: Revenue of 36.47 billion yuan, with a 25.5% increase, driven by strong performance in small molecule drug discovery and development [3] - WuXi Testing: After divesting clinical research services, revenue reached 4.04 billion yuan, a 4.7% increase, with drug safety evaluation business leading in the Asia-Pacific region [3] - WuXi Biology: Revenue of 2.68 billion yuan, a 5.2% increase, with over 20% new customer acquisition [3] Future Guidance - The company has a positive outlook for 2026, projecting revenue between 51.3 billion and 53 billion yuan, with stable adjusted Non-IFRS net profit margins [3][4] - The capital expenditure for 2026 is expected to be between 6.5 billion and 7.5 billion yuan, reflecting confidence in long-term growth [3][4]

Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec, indicating a positive outlook for the company's stock performance relative to the benchmark index [4]. Core Insights - WuXi AppTec exceeded its annual guidance, achieving record high performance in 2025 with a revenue of 45.456 billion yuan, a year-on-year increase of 15.8%. The adjusted net profit attributable to shareholders reached 14.96 billion yuan, up 41.3% year-on-year [4][5]. - The company has a strong order backlog of 58 billion yuan, reflecting a year-on-year growth of 28.8%. The TIDES business significantly contributed to the growth of the chemical segment, with a revenue increase of 96% year-on-year [4][5]. - The company expects a revenue forecast for 2026 to be between 51.3 billion and 53 billion yuan, with a year-on-year growth of 18-22% for its continuing operations [4][5]. Financial Performance Summary - In 2025, WuXi AppTec's revenue was 45.456 billion yuan, with a gross margin of 47.6%, an increase of 6.16 percentage points year-on-year. The net profit attributable to shareholders was 19.151 billion yuan, reflecting a 102.6% increase year-on-year [4][5]. - The company projects revenues of 52.28 billion yuan for 2026, with a profit growth rate of -8.6% due to high base effects from 2025 [5][6]. - The report highlights a significant improvement in profitability metrics, with a sales net margin of 42.53%, up 18.15 percentage points year-on-year [4][5]. Business Segment Performance - The chemical business generated 36.47 billion yuan in revenue, a 25.5% increase year-on-year, while the TIDES business alone contributed 11.37 billion yuan, marking a 96% increase [4][5]. - Revenue from U.S. clients grew by 34.3% to 31.25 billion yuan, while revenue from Europe and China saw slight declines [4][5]. - The report emphasizes the company's strong position in the global supply chain, unaffected by recent geopolitical tensions and trade conflicts [4][5]. Future Outlook - WuXi AppTec aims to enhance its technological capabilities and operational efficiency, with capital expenditures projected to reach 6.5-7.5 billion yuan in 2026 [4][5]. - The company anticipates adjusted free cash flow to be between 10.5 billion and 11.5 billion yuan in 2026, indicating strong cash generation potential [4][5]. - The report forecasts continued growth in the CRDMO sector, supported by a robust pipeline and global scale effects, positioning WuXi AppTec to lead the CXO industry [4][5].

Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec, indicating a positive outlook for the company's stock performance relative to the benchmark index [4]. Core Insights - WuXi AppTec achieved a record high in performance for the year 2025, with total revenue reaching 454.56 billion yuan, a year-on-year increase of 15.8%. The adjusted non-IFRS net profit was 14.96 billion yuan, up 41.3%, while the net profit attributable to shareholders was 19.15 billion yuan, reflecting a significant increase of 102.65% [4][5]. - The company reported a strong order backlog of 58 billion yuan, a year-on-year growth of 28.8%, driven by the TIDES business, which saw a revenue increase of 96% to 11.37 billion yuan [4][5]. - The revenue contribution from U.S. clients grew by 34.3% to 31.25 billion yuan, while European revenue decreased by 4% [4][5]. - For 2026, WuXi AppTec expects total revenue to be between 513 billion and 530 billion yuan, with a year-on-year growth of 18-22% in continuing operations [4][5]. Financial Performance Summary - In 2025, the company achieved a gross margin of 47.64%, an increase of 6.16 percentage points year-on-year, and a net profit margin of 42.53%, up 18.15 percentage points [4][5]. - The projected financials for 2026 include total revenue of 52.28 billion yuan, with a growth rate of 15%, and a net profit of 17.49 billion yuan, reflecting a decrease of 8.6% [5][6]. - The company’s EBITDA for 2025 was 27.87 billion yuan, with expectations for continued growth in subsequent years [7].

Core Viewpoint - WuXi Biologics reported record annual results for 2025, showcasing significant growth across various financial metrics, driven by strategic execution and increasing demand for complex biologics [1][19]. Financial Highlights - Revenue increased by 16.7% year-over-year (YoY) to RMB 21.8 billion, supported by the "Follow and Win the Molecule" strategy and rising demand for complex biologics [2][6]. - Gross profit rose by 30.9% YoY to RMB 10.0 billion, with gross margin expanding by 500 basis points to 46.0% [3][6]. - EBITDA grew by 38.1% YoY to RMB 9.0 billion, with an EBITDA margin of 41.5% [4][6]. - Net profit increased by 45.3% YoY to RMB 5.7 billion, driven by higher gross profits and gains from the investment portfolio [5][6]. Business Highlights - A record 209 new integrated projects were signed in 2025, bringing the total to 945, with strong contributions from U.S. clients [8][21]. - Research Services generated record-high payments, securing potential milestone and royalties exceeding US$4 billion [9][10]. - The Group supported 156 IND filings in 2025, expanding capacity to 200 INDs and 20 BLAs/MAAs annually [10][11]. Development and Manufacturing - Bispecifics and ADCs accounted for two-thirds of new project additions, reflecting a 30% growth in each modality [10][11]. - The Group maintained a 100% success rate in process performance qualifications (PPQs) and has 34 PPQs scheduled for 2026 [12][21]. - Total backlog reached US$23.7 billion, with US$4.5 billion expected within three years, indicating strong near-term revenue visibility [14][21]. Quality and Compliance - The Group has completed 46 regulatory inspections with no critical issues, maintaining a 100% pass rate for FDA Pre-License Inspections [15][19]. - The company has passed over 1,800 client GMP audits, demonstrating consistent quality and compliance standards [15][19]. Talent and Operational Efficiency - The workforce comprised 13,252 employees, including 4,885 scientists, with a talent retention rate of 96.4% [15][19]. - The WuXi Biologics Business System (WBS) contributed to gross margin improvement through over 430 Kaizen initiatives [16][19]. Sustainability and ESG - WuXi Biologics has been recognized for its ESG practices, achieving high ratings from global ESG rating agencies and inclusion in the Dow Jones Sustainability Indices [18][26].

Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][21] - The adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [11] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [12] - TIDES revenue nearly doubled, growing 96% year-over-year to RMB 11.37 billion [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [8] - Europe and China experienced declines mainly due to fluctuations in project delivery timing [8] Company Strategy and Development Direction - The company remains focused on enhancing its integrated CRDMO core business and improving operational efficiency to meet customer demand [23] - WuXi AppTec aims to sustain rapid business growth, expecting total revenue to reach RMB 51.3 billion - RMB 53 billion in 2026, with continuing operations revenue growing 18%-22% year-over-year [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic challenges, including currency exchange impacts and geopolitical uncertainties [30][31] - The company is committed to maintaining a stable and resilient adjusted non-IFRS net profit margin in 2026 [24] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [9] - The board proposed a cash dividend distribution plan totaling a record RMB 5.7 billion in 2026, maintaining a 30% annual cash dividend payout ratio [25] Q&A Session All Questions and Answers Question: How does management think about the impact of currency exchange? - Management acknowledged the FX movement and expressed confidence in their execution capabilities despite macroeconomic volatility [30] Question: How would you think about the impact of geopolitics and oil prices on your margins going forward? - Management noted that while there are potential risks to raw material costs, they have not seen direct impacts on operations and will monitor the situation closely [31] Question: What would be the next key modalities that could potentially be the new focus? - Management indicated that while peptide demand is high, they are also seeing growth in oligonucleotides, which could become a significant focus [32] Question: Have you sensed any change in client outsourcing strategy in the past six to 12 months? - Management stated that they are committed to improving capabilities and investing in capacities to meet customer needs, regardless of internal manufacturing trends in the pharmaceutical industry [35] Question: What is WuXi AppTec's positioning in oral small molecule GLP-1 CDMO business? - Management reported double-digit growth in the small molecule sector, with contributions from GLP-1 small molecules [46] Question: How do you see sustainability of TIDES business growth? - Management expressed confidence in sustained growth due to high demand for their largest products and a robust pipeline [54] Question: Can you give us some color on the general timeline that it takes for a new facility to be built? - Management stated that in China, a new facility can become fully operational in less than 12 months [57] Question: How is the current Middle East situation impacting the company's investment view in Saudi Arabia? - Management confirmed that their long-term strategy remains unchanged and they continue to engage with stakeholders in Saudi Arabia [60] Question: What is the company's view on relations between the U.S. and China? - Management expressed confidence that WuXi AppTec will not be included in the 1260H list and emphasized their transparent corporate governance [70]

Core Insights - WuXi Biologics has achieved significant advancements in 2025 through its CRDMO model, enhancing its position as a preferred partner for biopharmaceutical innovators and multinational corporations [1][2] - The company reported a record high of 209 new integrated projects in 2025, bringing the total to 945, with approximately 50% of these projects originating from U.S. clients [2][8] - WuXi Biologics is focusing on complex modalities, particularly bispecific/multispecific antibodies and ADCs, which now account for nearly 50% of its total project pipeline [4][8] Project Development - The company added 23 new projects in 2025, including 6 Phase III and commercial projects, with a significant portion involving complex modalities [5] - Bispecific/multispecific antibodies and ADCs have seen a growth of approximately 30%, reaching 196 and 252 projects respectively, contributing nearly 20% of the company's revenue with over 120% year-over-year growth [4][8] Research and Innovation - WuXi Biologics' research services achieved record-breaking upfront payments and potential milestone values exceeding USD 4 billion in 2025, driven by T-cell engager deals [7] - The CD3 platform has been widely adopted in the industry, enhancing the efficacy-safety balance of bispecific antibodies [6][7] Manufacturing Capabilities - The total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025, with a strong focus on operational excellence and technology leadership [11][12] - WuXi Biologics completed 28 PPQs in 2025, maintaining a success rate of over 99% and delivering more than 350 large-scale batches since 2017 [12][13] Global Expansion - The company is increasing strategic investments in the U.S. and has commenced construction of new facilities in Singapore, positioning these sites as strategic hubs within its global network [14][15] - An MOU was signed with the Qatar Free Zones Authority to establish a strategic site in Qatar, expanding WuXi Biologics' global footprint [16] Digital Innovations - WuXi Biologics has integrated digital innovations across its operations, achieving approximately 40% productivity gains and a 20% improvement in efficiency through smart manufacturing solutions [18] - The launch of the digital twin platform PatroLab aims to enhance process performance and ensure high-quality biologics manufacturing [18] Sustainability Efforts - The company has made significant strides in sustainability, earning an MSCI AAA Rating and being recognized in various sustainability indices [19][23] - WuXi Biologics is committed to driving green technology innovations and fostering positive social and environmental impacts [23] Future Outlook - In 2026, WuXi Biologics aims to build on its strong momentum with accelerated growth driven by robust research and manufacturing capabilities [20]